Therapy for persistent hypercalcemic hyperparathyroidism post-renal transplant: cinacalcet versus parathyroidectomy

Area of Science:

• Nephrology
• Endocrinology
• Transplant Surgery

Background:

• Persistent hyperparathyroidism post-kidney transplant is linked to increased cardiovascular events, fractures, and mortality.
• Treatment options include surgical parathyroidectomy (PTX) and the calcimimetic agent cinacalcet.

Purpose of the Study:

• To compare the efficacy and safety of parathyroidectomy (PTX) versus cinacalcet for managing persistent hyperparathyroidism in adult renal transplant recipients.
• To evaluate the impact of each treatment on calcium, phosphate, PTH levels, and renal function.

Main Methods:

• Retrospective single-center study of adult renal transplant recipients with hypercalcemia due to persistent hyperparathyroidism.
• Comparison of 30 patients treated with PTX against 46 patients treated with cinacalcet over a one-year follow-up period.
• Analysis of clinical and laboratory data, including serum calcium, phosphate, PTH, and creatinine levels.

Main Results:

• PTX achieved faster and more significant control of calcemia, reaching lower levels at 12 months compared to cinacalcet.
• PTX normalized PTH levels, whereas cinacalcet only decreased but did not correct PTH in most patients (95% remained with elevated PTH).
• Cinacalcet treatment was associated with better renal function (lower creatinine) compared to PTX.

Conclusions:

• Parathyroidectomy is superior to cinacalcet for correcting metabolic abnormalities in persistent hyperparathyroidism post-transplant.
• Despite superior metabolic control, PTX was associated with worse long-term renal function.
• Cinacalcet is a safe and well-tolerated alternative for managing hyperparathyroidism in this patient population.